[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"City Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100626035",false,"NCT07430397","A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation","A Phase 1, Randomised, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CITY-FXI, a FXI Targeting siRNA, Administered Subcutaneously in Healthy Adults and Adults With Factor V Leiden or Prothrombin G20210A Mutation","Inclusion Criteria:\n\n* Males and women of non-childbearing potential (WONCBP) aged 18 to 45 years (Part A only)\n* Male and female participants aged 18 to 60 (Part B only)\n* Body Mass Index (BMI) between 18 and 25 kg\u002Fm2 (inclusive) and a minimum weight of 50 kg\n* Ability and willingness to comply fully with all study procedures and lifestyle considerations\n* Confirmed diagnosis of FVL or prothrombin G20210A mutation via genetic testing (Part B only)\n* Women of childbearing potential (WOCBP) must agree to use acceptable highly effective contraceptive methods (Part B only)\n\nExclusion Criteria:\n\n* Any clinically significant systemic disease or disorder, including but not limited to cardiovascular, hepatic, or oncological conditions\n* History or evidence of any bleeding disorders\n* History of clinically significant spontaneous bleeding\n* Prior treatment with an investigational agent\n* Confirmed diagnosis of homozygous mutations, or combined thrombophilic defects of (Part B only)",true,"ALL","18 Years","60 Years",{"count":20,"type":21},128,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a first-in-human (FIH), single-center, randomised, double-blind, placebo-controlled, single ascending dose (SAD) study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CITY-FXI in healthy adults and adults with Factor V Leiden (FVL) or prothrombin G20210A mutation.",[27,28],"Factor V Leiden","Prothrombin G20210A",[30,31],"Factor XI","siRNA","RECRUITING","2026-02-18",{"date":35,"type":36},"2026-02-24","ACTUAL",{"date":38,"type":36},"2026-01-22",{"date":40,"type":21},"2027-10",{"name":42,"class":43},"City Therapeutics","INDUSTRY",""]